Shield Therapeutics PLC Investor Presentation (4596I)

TIDMSTX

RNS Number : 4596I

Shield Therapeutics PLC

14 December 2020

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Investor Presentation

London, UK, 14 December 2020: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces that it will provide a live presentation presented by CEO, Tim Watts, on Wednesday 16 December at 4.30pm.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Tim Watts, CEO                                             +44 (0)20 7186 8500 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     +44 (0)20 7220 0500 
 
 
   Financial PR & IR Advisor 
 Walbrook PR                       +44 (0)20 7933 8780 or shield@walbrookpr.com 
                                          +44 (0)7980 541 893 / +44 (0)7584 391 
 Paul McManus/Lianne Cawthorne                                              303

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru(R) is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUASKRRVUUAAA

(END) Dow Jones Newswires

December 14, 2020 02:00 ET (07:00 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024